NeoClinical Launches Neo PayPerPatient Solution for Asia-Pac
NeoClinical™, the leading digital clinical trial recruitment agency for Australia, New Zealand and Asian markets todayofficially launched its latest recruitment product, Neo PayPerPatient click here.
Neo PayPerPatient has emerged from 6 months of beta testing, including regulatory compliance, and integration of some of the latest online consumer engagement software and tools. Neo PayPerPatient has already built powerful databases of people wanting more information about the latest clinical trials for conditions including gout, arthritis, Alzheimer’s, menopause, diabetes, prostate cancer and asthma.
Neo PayPerPatient is a risk share pay-as-you-go solution for new studies or current studies that are underperforming and need a boost to recruitment. Sponsors only pay a nominal fee for partially screened patients then a moderate fee for those that proceed to full enrolment. NeoClinical™ manages all the rest. NeoClinical™‘s advertising and PR expertise as well as the team’s considerable online and social media experience to deliver results for clients. NeoClinical™ study recruitment campaigns feature innovative and EC compliant advertising, public relations and online content marketing campaigns.
NeoClinical™ typically achieves referral conversion rates of 40-60% and recently achieved a 63% conversion rate for a New Zealand Study.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
